July 14, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against IOVA

Core Viewpoint - The Gross Law Firm is notifying shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and a significant stock price decline following disappointing financial results [1][2]. Group 1: Allegations and Financial Performance - The class period for the allegations is from May 9, 2024, to May 8, 2025, during which Iovance allegedly provided overly positive statements while concealing material adverse facts about its growth potential [2]. - On July 25, 2024, Iovance announced its Q2 fiscal 2024 results and reduced its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in the case without any cost or obligation [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].